Cargando…
Mobilization of Circulating Tumor Cells after Short- and Long-Term FOLFIRINOX and GEM/nab-PTX Chemotherapy in Xenograft Mouse Models of Human Pancreatic Cancer
SIMPLE SUMMARY: To date, there has been no definite experimental evidence for the significance of circulating tumor cells (CTCs) as an indicator to estimate the chemotherapeutic effect in cancer patients. We previously reported a transient increase in CTC number 1 week after single-dose chemotherapy...
Autores principales: | Ito, Yukako, Kobuchi, Shinji, Kawakita, Amiri, Tosaka, Kazuki, Matsunaga, Yume, Yoshioka, Shoma, Jonan, Shizuka, Amagase, Kikuko, Hashimoto, Katsunori, Kanda, Mitsuro, Saito, Takuya, Nakanishi, Hayao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670901/ https://www.ncbi.nlm.nih.gov/pubmed/38001741 http://dx.doi.org/10.3390/cancers15225482 |
Ejemplares similares
-
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020) -
Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021) -
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021) -
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)